Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Operating Leases (2020 - 2026)

Nautilus Biotechnology has reported Operating Leases over the past 7 years, most recently at $25.0 million for Q1 2026.

  • Quarterly results put Operating Leases at $25.0 million for Q1 2026, down 14.72% from a year ago — trailing twelve months through Mar 2026 was $25.0 million (down 14.72% YoY), and the annual figure for FY2025 was $26.2 million, down 0.74%.
  • Operating Leases reached $25.0 million in Q1 2026 per NAUT's latest filing, down from $26.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $37.3 million in Q1 2023 and bottomed at $24.0 million in Q2 2025.
  • Median Operating Leases over the past 5 years was $28.6 million (2022), compared with a mean of $29.2 million.
  • The largest annual shift saw Operating Leases skyrocketed 2213.44% in 2022 before it decreased 26.51% in 2025.
  • Over 5 years, Operating Leases stood at $28.3 million in 2022, then grew by 9.72% to $31.1 million in 2023, then decreased by 15.15% to $26.4 million in 2024, then fell by 0.74% to $26.2 million in 2025, then dropped by 4.45% to $25.0 million in 2026.
  • Business Quant data shows Operating Leases for NAUT at $25.0 million in Q1 2026, $26.2 million in Q4 2025, and $27.0 million in Q3 2025.